



PRIZE PROGRAM DETAILS

The Rainwater Prizes for Neurodegenerative Research

Richard Rainwater, a renowned investor and visionary philanthropist, understood that the research he was funding may not be able to help him directly, but he knew the work was important, cutting edge and was going to inevitably lead to better treatments for patients like him in the future. He, therefore dedicated funds to develop a prize program that would launch when the progress in science was getting closer to helping patients. Mr. Rainwater passed away in 2015 from complications related to his progressive supranuclear palsy diagnosis, yet his legacy lives on in the fight to end neurodegenerative disease.

The Rainwater Charitable Foundation supports both K-12 education and medical research through its grantmaking. Within its medical research branch, the foundation created the Tau Consortium to help accelerate scientific progress, support high-risk/high-reward translational research and foster a highly collaborative environment. The members of the Tau Consortium are nominated to join the consortium through a scientific advisory committee. The Tau Consortium members work collaboratively, engage strategic partners and establish critical resources needed to accelerate progress towards understanding the underlying causes of neurodegenerative diseases like progressive supranuclear palsy, Alzheimer’s disease and other tauopathies.

The Rainwater Prize Program was designed to promote three prize categories, one of which is an annual prize, and the last two being milestone prizes that are only awarded upon achievement of defined goals. The objective of all the prize categories is to encourage and accelerate scientific progress toward new treatments for neurodegenerative diseases by; (a) enhancing awareness of the critical gaps in neurodegenerative research, (b) attracting researchers to work on tauopathies and (c) awarding scientific achievements leading to new treatments for PSP.

The Prizes are as follows:

	PRIZE AMOUNT	TIMING
The Rainwater Prize for Outstanding Innovation in Neurodegenerative Research	\$250K	Every Year
The Rainwater Milestone Prize for Advances in Tauopathy Research	Up to \$2M	When Milestones and eligibility are met
The Rainwater Breakthrough Prize for Effective Treatments in PSP	\$2M to \$10M	When breakthrough treatments are in the clinic and eligibility is met

This is the first year of the prize program with the first prize(s) to be awarded in November 2019. While the Rainwater Prize for Outstanding Innovation in Neurodegenerative Research annual prize will be awarded in 2019, and awarded each year thereafter, the Milestone and Breakthrough prizes may or may not be awarded based on this year’s nominations and discoveries. All awards may be awarded to individuals or shared as teams at the discretion of the selection committee.

TABLE OF CONTENTS

Section 1	The Rainwater Prize for Outstanding Innovation in Neurodegenerative Research	3
Section 2	The Rainwater Milestone Prize for Advances in Tauopathy Research	3
	Milestone Categories	3
Section 3	The Rainwater Breakthrough Prize for Effective Treatments in PSP	4
	Breakthrough Categories	4
Section 4	Eligibility of Nominees and Nominators	4
Section 5	Application Process	5
Section 6	The Review Process	5
	Timeline for Review Committee	6
Section 7	The Evaluation Criteria	6
Section 8	Confidentiality	7
Section 9	Conflict of Interest	7
	Criteria for recusal of selection committee members	7
	Implicit bias	7
Section 10	Liability and Indemnity	7
Section 11	Other	8

Section 1 The Rainwater Prize for Outstanding Innovation in Neurodegenerative Research

This annual award recognizes investigator(s) whose work is considered a significant contribution to our understanding of neurodegenerative diseases with a preference for Tau-related discoveries. Nominees will be considered through a non-self-nomination process for published, peer-reviewed tau-related research. The nominations are open for all researchers, from all countries, and research institutional affiliations. Awardees will be chosen by a committee of international scientific leaders from a wide range of fields and backgrounds. Awardees will be chosen primarily based on their scientific contributions. Other factors, such as leadership, mentorship, and overall contributions to the scientific community, will also be considered.

This award will consist of a \$250K prize provided through a fund created by Richard Rainwater at the North Texas Community Foundation. Recipients will only be able to use the funds for charitable purposes.

The awardee(s) will be honored at an award presentation ceremony at a location TBD in November 2019. All travel expenses for awardee(s) and family members will be covered by the foundation. The awardee will also present their findings at the Rainwater Charitable Foundation's next major scientific conference.

Section 2 The Rainwater Milestone Prize for Advances in Tauopathy Research

This award recognizes investigator(s) whose work is considered a significant contribution to our understanding of Tau-related diseases by addressing critical gaps in technology and/or disease knowledge that have the potential to help the scientific community develop effective treatments. Nominees will be considered through a non-self-nomination process for published, peer-reviewed tau-related research and demonstration of open sharing of data and technology or models. The nominations are open for all researchers, from all countries, and research institutional affiliations. Awardees will be chosen by a committee of international scientific leaders from a wide range of fields and backgrounds. The awardee will be chosen based on their scientific contributions to the specified milestones, demonstrated willingness to collaborate and share scientific resources, leadership, mentorship, and overall contributions to the scientific community. This prize will be awarded upon milestone completion and may or may not be awarded each year. This prize may be awarded to individuals or teams of scientists.

The 2018/2019 Milestone Prize categories are:

Structure, Function, and Disease Mechanisms

- Tau protein modifications and how these function in health and disease
- Mechanism of Tau aggregation and transmission (inside and outside cell)
- Mechanism of glial and neuronal loss (Tau? Or Inflammation? Or other?)

Risk and Prevention

- Genetic/Epigenetic early detection
- Predictors of Tau normal vs. dysfunction
- Progression monitoring
- Polygenic risk assessment
- Clinical trial stratification
- Biomarkers
- Advances in drug development

Models and Technology

- Mouse or other *in vivo*, clinically relevant model

- Clinical drug efficacy prediction models
- Stem cell (iPSCs)
- 3D organoid
- CRISPR
- Advances in imaging

This award will vary from \$50K to \$2M, depending on the nature of the specific challenge. Awards will be provided through a fund created by Richard Rainwater at the North Texas Community Foundation. Recipients will only be able to use the funds for charitable purposes.

If awarded, the awardee(s) will be honored at an award presentation ceremony at a location TBD in November 2019. All travel expenses for awardee(s) and family members will be covered by the foundation. The awardee will also present their findings at the Rainwater Charitable Foundation’s next major scientific conference.

Section 3 The Rainwater Breakthrough Prize for Effective Treatments in PSP

This award recognizes investigator(s) whose work is considered a significant contribution to the development of effective treatments for PSP. Nominees will be considered through a non-self-nomination process for published, peer-reviewed PSP-related research that led to a treatment that has significant improvement of welfare for patients. The nominations are open for all researchers, from all countries, and research institutional affiliations. Awardees will be chosen by a committee of international scientific leaders from a wide range of fields and backgrounds. The awardee will be chosen based on their scientific contributions that ultimately led to the development of treatments for PSP. Other factors will be considered, such as a demonstrated willingness to collaborate and share scientific resources, leadership, mentorship, and overall contributions to the scientific community. This prize will be awarded to the basic science, translational research that led to the development and clinical use of a treatment with significant, measurable improvement of life for PSP patients. This prize is unlikely to be awarded each year and may ultimately be awarded to individuals or teams of scientists.

The 2018/2019 Breakthrough Prize categories are:

<u>FDA approved treatment that meaningfully extends good quality of life for patients</u>	-	\$2M
<u>FDA approved treatment that cures PSP early in progression</u>	-	\$4M
<u>FDA approved treatment that prevents PSP and/or reverses disease damage</u>	-	\$10M

This award will be provided through a fund created by Richard Rainwater at the North Texas Community Foundation. Recipients will only be able to use the funds for charitable purposes.

If awarded, the awardee(s) will be honored at an award presentation ceremony at a location TBD in November 2019. All travel expenses for awardee(s) and family members will be covered by the foundation. The awardee will also present their findings at the Rainwater Charitable Foundation’s next major scientific conference.

Section 4 Eligibility of Nominees and Nominators

Eligible Nominees must:

- Have made significant contributions to research in Tau-related diseases within the scope of the prize for which the nominee is being considered.
- Except for the breakthrough prize, all other prize nominees must have made the discovery within the last 10 years.

The following are not eligible:

- Self-nominations
- Past recipients of the same award

Anyone can nominate an individual. Nominations are limited to one (1) per nominator per calendar year for each prize.

Section 5 Application Process

Anyone is eligible to submit one nomination for an award, and only one nomination per calendar year. Self-nominations are not permitted. Nominations will be submitted through an online nomination form beginning on November 5th, 2018. Nomination will remain open until April 26th, 2019.

The Rainwater Charitable Foundation will contact the eligible nominees to request a recent curriculum vitae (CV), two letters of reference, and a standard release and background check form. Completed applications submitted no later than May 10th, 2019 will be prescreened for continued eligibility and reviewed by the selection committee.

The nominee selected for an award will be contacted by October 2019 to confirm acceptance of the award and the terms of the award. The awardee must be able to accept the award at a ceremony with location TBD in November 2019 and give a talk in a TBD location of a Rainwater Charitable Foundation conference. The awardee must allow for his/her photo, information of award, ceremony details and discovery contributions to be publicly available. If the award is not accepted, or if the recipient is no longer eligible, the nominee is required to keep all notices around their selection confidential. An awardee that accepts the award must keep all results of the prize competition confidential until the Rainwater Charitable Foundation official award announcement is released.

Section 6 The Review Process

Nominations for the 2019 prize cycle will open in November of 2018 and close in April 2019. The initial vetting of nominations by verification of eligibility and scientific literature review will be done by the Rainwater Charitable Foundation staff. The top 40 nominations will receive email communications notifying them of their nomination and requests for updated CV, letters of reference, and signed release and background check consent. The next round of vetting will confirm that all nominees are eligible for their respective prize categories for which they were nominated.

The selection committee will be responsible for determining recipient(s) of the Rainwater Prize. The selection committee will be composed of 7 to 10 leaders in neuroscience, translational medicine, advocacy and community. The committee will also consist of a non-voting chair who will lead the committee and allow for a

fully diverse and balanced conversation between voting members. In May 2019, the selection committee will have a group conference call to discuss the prize statistics including number of nominations and for which prize categories they will be judging. In June 2019, the prize committee will receive the top eligible nominee application materials including a list of other nominees. Should a selection committee member believe that one of the non-priority nominees should be a finalist, they can elect to pull a nominee into the top finalist list. Members of the selection committee must submit their potential recusals at least 7 days before the voting date. Members of the selection committee will have an in-person meeting at a location TBD in July 2019 to vote on the Rainwater Prize recipient(s). On the day before voting, there will be a hosted dinner where they will submit their rankings of the top finalists to the Rainwater Charitable Foundation staff. These rankings will serve as discussion points for the next day of voting. On the following morning, the selection committee will meet to discuss the top ranked nominees, 2 minutes each in each category. Voting will begin until a consensus is met where all members agree on the recipient(s) of the award(s). If after 2 hours of discussion a unanimous vote does not occur, the voting structure will allow an awardee with 7 out of 10 votes. The timeline for the selection committee is as follows:

Section 7 The Evaluation Criteria

Nominees that meet all eligibility criteria and preliminary screening will be reviewed by the selection committee. The following criteria will be used to evaluate the applications for the Rainwater Prize Program:

Research Discovery (Weight 70%) The nominee must have contributed significantly to the discovery for which the award category outlines. The scope of review will involve applicability to award nominated for, quality of peer-reviewed research findings, validation by the scientific community, research citations, significant impact for neurodegenerative disease, applicability to a tauopathy, contribution to development of technology or platform, and the extent to which the findings have been incorporated into common teaching and across the scientific community.

Leadership (weight 30%) The nominee must be in good standing within their institution and within the scientific community. The nominee(s) are evaluated based on their level of collaboration, data sharing and technology sharing. The nominee(s) is evaluated on their leadership, mentoring, trainee success and role model impact. The nominee(s) are evaluated based on their internationally known thought leadership, their engagement in diversity and equity and their overall contributions to the scientific community through outreach and education.

A nominee's general societal contributions will be taken in to account should all other scoring between scientific contributions and leadership among top candidates be considered equal.

Section 8 Confidentiality

For the Selection Committee: The information passed on to the selection committee regarding the prize program details, details of the nominees, nominators and associated research projects and programs both published and unpublished will remain confidential within the selection committee. Awardees decided by the selection committee will remain confidential until such time that the Rainwater Charitable Foundation makes the decision public. However, the information in the application applicable to the awarding of the Rainwater Prize may be used by the Rainwater Charitable Foundation at any time for publicity or promotional purposes.

For the Awardee: Nominees who have been voted to receive one of the Rainwater Prizes will be subject to the above confidentiality as per the selection committee. If the award is not accepted, or the recipient no longer eligible, the nominee is required to keep all notices around their selection confidential. An awardee that accepts the award must keep all results of the prize competition confidential until the Rainwater Charitable Foundation releases the official award announcement.

Section 9 Conflict of Interest

All selection committee members must disclose any conflicts of interest no less than 7 days before the date of in-person voting. Any real or perceived conflicts should be reported and discussed with the selection committee Chair. Conflicts of Interests that require recusal include but are not limited to: if the selection committee member is a relative, business partner, active scientific collaborator, recent (within 5 years) co-author, former advisor, or former student of the nominee. If the selection committee member is currently employed by the same institution as the nominee the Chair must be notified, however this is not considered immediate grounds for conflict of interest and recusal. The committee chair will inform the committee members of these relationships.

In addition to conflict of interest, the committee chair will discuss implicit bias with the selection committee. These associations include but are not limited to attitudes or biases an individual brings towards words, names or ideas, conscious hypotheses/stereotypes including those concerning competence that could discourage diversity in the selection process.

Section 10 Liability and Indemnity

All nominees and nominators pursuant to the Rainwater Prize Program acknowledge and agrees that in responding to the program announcement that the nominee and the nominator shall have no claim against the Rainwater Charitable Foundation, its respective representatives, related companies or affiliates, should such Program response be unsuccessful for any reason. Each nominee and nominator hereby remise and releases the Rainwater Charitable Foundation and all representatives and affiliates from any cause of action, complaint, or claim in connection with the call for nominations process and its outcome.

The Rainwater Charitable Foundation's role is that of a funder. The Rainwater Charitable Foundation is not the sponsor of funded projects. The Rainwater Charitable Foundation will not assume any liability associated with the funded research projects and each awardee who is selected as a recipient pursuant to the Rainwater Prize Program releases the Rainwater Charitable Foundation from any and all liability with respect thereto and further indemnifies the Rainwater Charitable Foundation, and its respective representatives and affiliates, from any claim or loss whatsoever associated with the applicable award.

Section 11 Other

The Rainwater Charitable Foundation reserves the right to accept or reject any or all applications for the Rainwater Prize program. The Rainwater Charitable Foundation reserves the right to negotiate the terms of the specified award agreement with the awardee and his/her research or affiliated institution. The foundation may, at its sole discretion, change the timeline of the nomination and award process, and/or the recipient of the

award. The foundation may at its discretion award multiple awards, no awards and/or split awards between two or more individuals.

The submission of a nomination or application does not bind either the foundation, the nominee or the nominee's affiliated institution by any commitment to provide or receive the award, respectively.